SCHEMBL16308656

SCHEMBL16308656

O=C(CO)N1CCC(Oc2ccc(Br)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.56
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.47
HTT P42858 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CCR5 P51681 1/20 0.46
MMP1 P03956 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
GPR183 P32249 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NAMPT P43490 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18318164 0.87 EPHX2 (0.54) POLBKMT2AALDH1A1MEN1MAPT
SCHEMBL3347314 0.83 CCR5 (0.49) POLBKMT2AALDH1A1MAPTHTT
SCHEMBL31370640 0.82 ALDH1A1 (0.55) POLBKMT2AALDH1A1MEN1CCR5
SCHEMBL10609014 0.82 CCR5 (0.48) POLBKMT2AALDH1A1HTTCCR5
SCHEMBL18318789 0.79 EPHX2 (0.49) POLBALDH1A1MAPTHTTCYP1A2
SCHEMBL18318787 0.79 EPHX2 (0.49) POLBALDH1A1MAPTHTTCYP1A2
SCHEMBL23410109 0.78 CHRNA7 (0.46) POLBKMT2AALDH1A1MAPTHTT
SCHEMBL21801725 0.78 NAMPT (0.53) POLBKMT2AALDH1A1MEN1L3MBTL1
SCHEMBL17279135 0.78 ALK (0.55) POLBALDH1A1CCR5NAMPT
SCHEMBL29067466 0.78 POLB (0.47) POLBALDH1A1MAPTHTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9580390-B2 Indazole compounds as kinase inhibitors and method of treating cancer with same UNIVERSITY HEALTH NETWORK (CA) 2017-02-28 US disclosed
US-9580390-B2 Indazole compounds as kinase inhibitors and method of treating cancer with same UNIVERSITY HEALTH NETWORK (CA) 2017-02-28 US disclosed
US-20140371202-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2014-12-18 US disclosed
US-20140371202-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371202-A1 INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME PLK4, PLK2, PLK3 POLB 640/4885KMT2A 1936/4885ALDH1A1 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.